HC Wainwright Estimates Sutro Biopharma FY2030 Earnings

Sutro Biopharma, Inc. (NASDAQ:STRO) – Equities researchers at HC Wainwright issued their FY2030 earnings estimates for shares of Sutro Biopharma in a research note issued to investors on Tuesday, March 24th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings per share of ($4.43) for the year. HC Wainwright currently has a “Buy” rating and a $28.00 target price on the stock. The consensus estimate for Sutro Biopharma’s current full-year earnings is ($2.92) per share.

Several other brokerages have also commented on STRO. Wells Fargo & Company upgraded Sutro Biopharma from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $8.00 to $27.00 in a report on Tuesday. Citizens Jmp raised Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 target price on the stock in a research report on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft increased their price target on Sutro Biopharma from $51.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday. Citigroup raised Sutro Biopharma to an “outperform” rating in a report on Tuesday, January 20th. Finally, Wedbush restated a “neutral” rating and set a $100.00 price target (up from $20.00) on shares of Sutro Biopharma in a research note on Tuesday, December 2nd. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $37.29.

Sutro Biopharma Trading Down 0.3%

NASDAQ STRO opened at $23.50 on Wednesday. The firm’s fifty day simple moving average is $18.61 and its two-hundred day simple moving average is $12.76. Sutro Biopharma has a 12-month low of $5.23 and a 12-month high of $26.54. The firm has a market capitalization of $199.99 million, a P/E ratio of -0.90 and a beta of 1.47.

Institutional Trading of Sutro Biopharma

Large investors have recently added to or reduced their stakes in the company. Bridgeway Capital Management LLC increased its holdings in shares of Sutro Biopharma by 232.6% in the third quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock valued at $37,000 after purchasing an additional 30,000 shares during the period. Invesco Ltd. boosted its position in Sutro Biopharma by 137.8% in the first quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock valued at $60,000 after buying an additional 53,390 shares during the last quarter. Cerity Partners LLC boosted its position in Sutro Biopharma by 169.9% in the second quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock valued at $75,000 after buying an additional 66,372 shares during the last quarter. Qube Research & Technologies Ltd acquired a new position in Sutro Biopharma in the 2nd quarter worth approximately $82,000. Finally, State of Tennessee Department of Treasury purchased a new position in Sutro Biopharma during the 4th quarter worth approximately $86,000. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Trending Headlines about Sutro Biopharma

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Deutsche Bank raised its price target on STRO to $55 (from $51) and kept a Buy rating — a materially higher target that suggests strong upside vs. the current share price and supports bullish investor expectations. Deutsche Bank raises PT to $55
• Positive Sentiment: Wells Fargo upgraded STRO from Equal Weight to Overweight and raised its price target to $27 (from $8), signaling improving institutional sentiment and providing a nearer-term upside anchor for the stock. Wells Fargo upgrade
• Positive Sentiment: HC Wainwright upgraded STRO from Neutral to Buy and raised its target to $28 (from $10). The firm also published FY2030 EPS projections (large negative EPS expected), but maintained a Buy stance and higher target — a supportive signal from a biotech-focused shop. HC Wainwright upgrade HC Wainwright EPS note
• Neutral Sentiment: Short-interest reports for March show anomalous values (reported as 0 shares with NaN changes and 0.0 days-to-cover across different volume baselines). The data appears unreliable or reflects a reporting/clearing event, so its immediate impact on price is unclear. (Multiple internal short-interest notices consolidated)

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.